Biotech: Page 3


  • tangled knot between two businessmen walking a tightrope
    Image attribution tooltip
    Cemile Bingol via Getty Images
    Image attribution tooltip

    The fortunes and flops of pharma M&A

    Hindsight offers a better perspective on why some deals are fruitful and others fail.

    By Alexandra Pecci • Dec. 4, 2023
  • Portrait of John Mulligan, chief executive officer of Bonum.
    Image attribution tooltip
    Permission granted by Bonum Therapeutics
    Image attribution tooltip

    How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

    John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

    By Nov. 30, 2023
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Header image for "Creating a Compelling IPO Roadshow Presentation"
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Biopharma’s top 5 IPOs of 2023 (so far)

    Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

    By Alexandra Pecci • Nov. 28, 2023
  • alcohol bottles illustration
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

    By Kelly Bilodeau • Nov. 27, 2023
  • body muscle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

    By Kelly Bilodeau • Nov. 20, 2023
  • man in dark tunnel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    ​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

    The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

    By Nov. 17, 2023
  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

    By Nov. 16, 2023
  • Genomics DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

    By Alexandra Pecci • Nov. 15, 2023
  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

    By Nov. 15, 2023
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Can Sarepta’s Duchenne gene therapy still deliver on its promise?

    For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

    By Kelly Bilodeau • Nov. 14, 2023
  • moquito art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

    The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

    By Kelly Bilodeau • Nov. 13, 2023
  • Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes
    Image attribution tooltip

    stock.adobe.com/master1305

    Image attribution tooltip
    Sponsored by ClinicalMind

    Optimizing KOL engagement and technology utilization in 2024

    What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

    Nov. 13, 2023
  • ceo pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 of the best paid biopharma CEOs

    As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

    By Alexandra Pecci • Nov. 10, 2023
  • Jean Jacques Bienaime headshot
    Image attribution tooltip
    Permission granted by BioMarin
    Image attribution tooltip
    Making Moves

    Does BioMarin’s CEO shuffle signal bigger changes ahead?

    With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

    By Nov. 9, 2023
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How pharma leaders talk about ethics in a highly criticized industry

    The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

    By Nov. 9, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , Nov. 9, 2023
  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    An at-home flu vaccine? If approved, it could open the door to more DIY options

    A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

    By Kelly Bilodeau • Nov. 8, 2023
  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

    By Kelly Bilodeau • Nov. 8, 2023
  • Anne Wojcicki red carpet
    Image attribution tooltip
    Dia Dipasupil via Getty Images
    Image attribution tooltip
    Q&A

    23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

    23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

    By Alexandra Pecci • Nov. 7, 2023
  • Arthur Caplan, professor of bioethics and founding head of the Division of Medical Ethics, NYU’s Grossman School of Medicine
    Image attribution tooltip
    Permission granted by NYU
    Image attribution tooltip
    Opinion

    The thorniest questions facing pharma, according to a leading bioethicist

    Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

    By Nov. 6, 2023
  • Entrepreneur heeader
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Entrepreneurs

    From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

    By Nov. 3, 2023
  • dollar sign blowing away
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    In a record year for biotech bankruptcy, here are 3 companies that went under

    A challenging funding environment and lack of partnering deals have contributed to the market's ongoing troubles.

    By Alexandra Pecci • Nov. 2, 2023
  • robot hand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls

    From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.

    By Kelly Bilodeau • Nov. 1, 2023
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    What’s next for COVID dark horse Novavax?

    Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

    By Kelly Bilodeau • Oct. 30, 2023
  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By Oct. 27, 2023